Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-peptide vaccine in HER2-moderate solid tumors
NCT02276300Phase 1Completed
- Sponsor
- Technical University of Munich
- Start
- Dec 2014
- Primary completion
- Jul 2017
- Modality
- Cytokines & Interferons, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelipepimut-S in breast cancer and gastric cancer (GC), sponsored by Technical University of Munich. Primary endpoint: Safety and tolerability of HER2-derived peptide vaccination at 113 days. Started Dec 2014; status: completed.
02
Drugs
nelipepimut-S
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02276300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276300.